Brief: Tharimmune Announces Positive Data With Novel Biparatopic PD-1/VEGF & Multispecific HER2/HER3 Biologics Leveraging Proprietary Epiclick(TM) Technology
07/04/2025 13:39
April 7 (Reuters) - Tharimmune Inc THAR.O: THARIMMUNE:POSITIVE DATA WITH NOVEL BIPARATOPIC PD-1/VEGF AND MULTISPECIFIC HER2/HER3 BIOLOGICS LEVERAGING PROPRIETARY EPICLICK(TM) TECHNOLOGY Source text: [ID:] Further company coverage: THAR.O ((Reuters.Briefs@thomsonreuters.com))
Recent news on Canton Strategic Holdings
See all newsBrief: Canton Strategic Holdings, Inc. Expected To Be Included In Russell 3000® And Russell 2000®
Brief: Canton Strategic Authorizes Share Repurchase Program For Up To $50 Million In Common Stock
Canton Strategic Holdings Q1 net loss widens on higher expenses
Brief: Canton Strategic Holdings Reports Full Year 2025 Financial And Operational Results
Brief: Canton Strategic Holdings Inc - Enters Amended Sales Agreement With Clear Street And Virtu Americas - SEC Filing